Health Library › Health News

Health News

What new research suggests about glp-1 drugs in adolescents

GLP-1 medications are drawing more attention as a possible tool for treating obesity in adolescents,

Article Updated: November 17, 2026 6 min read

GLP-1 medications are drawing more attention as a possible tool for treating obesity in adolescents, but the story is still developing. A CBS News report published November 17, 2026, pointed to a study suggesting these drugs could help some adolescents with obesity, while also underscoring that the evidence is still evolving and needs careful interpretation.

That matters because obesity treatment in younger patients often involves long-term planning, not just short-term weight loss. The question for families and clinicians is not only whether GLP-1 medicines can reduce weight, but also how well they fit into broader care, what side effects they may cause, and how much is still unknown about long-term use during adolescence. https://www.cbsnews.com/video/glp-1-use-could-offer-help-for-obese-adolescents-study-shows/

What happened

The CBS report focused on a new study discussed by a pediatric endocrinologist, which described promising results for GLP-1 use in adolescents with obesity. The report did not frame the drugs as a stand-alone fix; instead, it presented them as one possible option in a larger treatment picture. https://www.cbsnews.com/video/glp-1-use-could-offer-help-for-obese-adolescents-study-shows/

That is consistent with the broader medical landscape. The FDA has already approved semaglutide (Wegovy) for chronic weight management in pediatric patients ages 12 and older with obesity, and the National Institute of Diabetes and Digestive and Kidney Diseases says the FDA has approved several prescription weight-management medicines for children 12 and older. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215256Orig1s005ltr.pdf

Advertisement

Why it matters

Obesity during adolescence can affect cardiometabolic health, and clinicians have been looking for therapies that work beyond lifestyle changes alone. GLP-1 receptor agonists are already used in adults and are increasingly being studied in younger patients because they can influence appetite, satiety, and some metabolic measures. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity

Recent research in PubMed adds to that interest. A 2026 network meta-analysis comparing GLP-1 receptor agonists in children and adolescents with obesity found that these medicines showed different cardiometabolic profiles, indicating that not all drugs in the class perform exactly the same way. A separate systematic review and meta-analysis found that, compared with placebo, GLP-1 receptor agonists were associated with reductions in BMI, body weight, waist circumference, hemoglobin A1c, and systolic blood pressure in pediatric obesity trials. https://pubmed.ncbi.nlm.nih.gov/42401410/

Those findings help explain why interest is growing. They do not mean every adolescent should take a GLP-1 drug, and they do not prove that a medication will prevent future diabetes or other complications in any individual patient. They do show that the class is being studied seriously as part of pediatric obesity care. https://pubmed.ncbi.nlm.nih.gov/42401410/

What the evidence actually shows

The strongest evidence to date comes from clinical trials and systematic reviews, not from a single story or a single clinic experience. The FDA’s pediatric approval for semaglutide reflects the fact that the drug has already been evaluated for weight management in younger patients, and the agency notes that the indication is for patients 12 years and older with obesity. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215256Orig1s005ltr.pdf

At the same time, newer studies suggest the effects may extend beyond the scale. Researchers have reported changes in cardiometabolic measures and body composition in adolescents treated with GLP-1 receptor agonists, although much of this work is still relatively recent and often observational or limited in size. That means it can support hypotheses and guide further research, but it does not settle every question about long-term benefit or risk. https://pubmed.ncbi.nlm.nih.gov/42011014/

Advertisement

Safety is part of the picture too. The FDA labeling for semaglutide includes warnings about adverse effects that matter in everyday care, including gastrointestinal side effects and the need for caution around surgery or deep sedation. The label also notes that coadministration with other semaglutide-containing products or with another GLP-1 receptor agonist is not recommended. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf?category=IF

What remains uncertain

Even with encouraging findings, several issues are still unresolved. Researchers are still working out how long adolescents should stay on treatment, what happens if the medication is stopped, and whether benefits on weight and metabolic markers translate into long-term health outcomes later in life. The recent reviews also make clear that the pediatric evidence base is still smaller than the adult one. https://pubmed.ncbi.nlm.nih.gov/42508693/

Another open question is how these medicines perform in real-world care outside a trial setting. Recent retrospective studies and reviews suggest potential benefits, but those designs are more vulnerable to bias than randomized trials. That is why medical experts generally treat these findings as promising, not definitive. https://pubmed.ncbi.nlm.nih.gov/42011014/

There are also practical questions about access, monitoring, and tolerability. For many patients, the biggest barriers are not just whether a drug works, but whether it can be used consistently, safely, and affordably over time. Those issues are especially important when treatment is being considered for a younger person who may need ongoing follow-up. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity

What to discuss with a clinician

If a family is considering a GLP-1 medicine for obesity treatment, the conversation should cover more than weight loss alone. It is reasonable to ask how the medication fits with nutrition, physical activity, sleep, mental health, and any other medical conditions. It is also important to ask about side effects, what monitoring will be needed, and whether the medicine is approved and appropriate for the patient’s age and health profile. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity

Because these drugs can affect digestion and are relevant around anesthesia and procedures, patients should tell their care team about all medications before surgery or sedation. Anyone with severe symptoms such as persistent vomiting, signs of dehydration, severe abdominal pain, or trouble keeping fluids down should seek urgent medical attention rather than waiting for a routine visit. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf?category=IF

For now, the takeaway is measured rather than dramatic: GLP-1 drugs are becoming a more important part of the obesity-treatment conversation for adolescents, but the evidence is still accumulating. The latest research adds support for their use in selected patients, while also making clear that long-term questions remain. https://www.cbsnews.com/video/glp-1-use-could-offer-help-for-obese-adolescents-study-shows/

Sources

Glp-1 use is tilting toward weight loss, and that matters Next article → Glp-1 use is tilting toward weight loss, and that matters

Was this article helpful?

Free newsletter

Get the Daily Health View briefing

The day's most important health news, explained clearly. One short email a day. Unsubscribe anytime.

Share this article

Found this useful? Share it with someone who may benefit from it.

Author

Daily Health View Editorial Team

Health & Wellness Editorial Desk

The Daily Health View Editorial Team prepares educational health content with an emphasis on clarity, responsible presentation and reference-based information.

Daily Health View Editorial content Updated November 17, 2026